Summary: Tocilizumab is a novel monoclonal antibody that competitively inhibits the binding of interleukin-6 (IL-6) to its receptor (IL-6R). Inhibiting the entire receptor complex prevents IL-6 ...

Interleukin 2 (IL-2) is the only systemic treatment currently available that is capable of curing patients with metastatic renal cell cancer (RCC). The first indications that IL-2 could mediate ...

Getting seven experiments on the International Space Station requires a really good idea. Like a brand new way to attack ...

Adults and adolescents treated with icotrokinra experienced improvements in their moderate to severe plaque psoriasis, ...

Two-thirds of patients with moderate or severe plaque psoriasis had complete or nearly complete clearance at 4 months with an ...

P J Tyrrell, N J Rothwell, S J Hopkins, A Vail, H C A Emsley, C J Smith, R F Georgiou, C M Gavin, E M Barberan, A Parry-Jones, J Selvarajah, J Staniland, C Sherrington, D G Hughes, IW Turnbull, G ...

Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of ...

Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination ...

In addition, CM can also regulate the expression and signaling pathway of IL-17, further inhibit inflammatory response and improve the symptoms of CHD, providing a new idea and method for the ...

A new study reveals that Epstein-Barr virus (EBV) infection exacerbates ulcerative colitis (UC) by driving macrophage ...

Tourmaline Bio (NASDAQ:TRML – Get Free Report) had its price objective lifted by analysts at HC Wainwright from $49.00 to $50.00 in a research report issued on Friday,Benzinga reports. The firm ...